Mantle cell lymphoma (MCL) is a rare (5-7%), aggressive B-cell non-Hodgkin's lymphoma with well-defined hallmarks (e.g. Cyclin D1, SOX11), and whose expansion is highly dependent on the tumor microenvironment (TME). Parallel drastic progresses in the understanding of the lymphomagenesis and improved treatments led to paradigm shift in this B-cell malignancy with now prolonged disease-free survival after intensive chemotherapy and anti-CD20 based maintenance. However, this toxic strategy is not applicable in frail or elderly patients and a small but significant part of the cases will present a refractory disease representing unmet medical needs. Importantly, the field has recently seen the rapid emergence of targeted and immune-based strategies with effective combinations relying on biological rationales to overcome malignant plasticity and intratumor heterogeneity. In this review, we expose how unraveling the biology of MCL allows to better understand the therapeutic resistances and to identify neo-vulnerabilities of tumors, which are essential to offer efficient novel strategies for high-risk patients. We first highlight the tumor intrinsic resistance mechanisms, and associated Achilles heels within various pathways such as NFkB, mitochondrial apoptosis, DNA repair or epigenetic regulators. We then place the tumor in its complex ecosystem to decipher the dialog with the multiple TME components and show how the resulting protumoral signals could be disrupted with innovative therapeutics strategies. Finally, we discuss how these progresses could be integrated in a personalized approach in MCL.
Skip Nav Destination
Review Article|
March 29, 2024
Unraveling MCL biology to understand resistance and identify vulnerabilities
clémentine Sarkozy,
clémentine Sarkozy
Institut Curie, Hematology department, Saint Cloud, France
Search for other works by this author on:
Benoit Tessoulin,
Benoit Tessoulin
Nantes University Hospital, Nantes, France
Search for other works by this author on:
David Chiron
Nantes Université, Inserm, CNRS, Université d'Angers, CRCI2NA, Nantes, France
* Corresponding Author; email: david.chiron@univ-nantes.fr
Search for other works by this author on:
Blood blood.2023022351.
Article history
Submitted:
January 29, 2024
Revision Received:
March 8, 2024
Accepted:
March 15, 2024
Citation
clémentine Sarkozy, Benoit Tessoulin, David Chiron; Unraveling MCL biology to understand resistance and identify vulnerabilities. Blood 2024; blood.2023022351. doi: https://doi.org/10.1182/blood.2023022351
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal